Suchergebnisse - "Oluwole, Olalekan O"

PubPharm (20)

1

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting : An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

enthalten in: Transplantation and cellular therapy | 2024

von Oluwole, O. | Dholaria, B. | Knight, T. | +12

2

Chimeric Antigen Receptor T Cell Therapy for Myeloma : Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

enthalten in: Transplantation and cellular therapy | 2024

von Anderson, L. | Dhakal, B. | Jain, T. | +5

3

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

enthalten in: Blood advances | 2023

von Bhaskar, S. | Patel, V. | Porter, D. | +12

4

Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma

enthalten in: Transplantation and cellular therapy | 2023

von Ahmed, N. | Wesson, W. | Mushtaq, M. | +16

5

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

enthalten in: Blood | 2023

von Neelapu, S. | Jacobson, C. | Ghobadi, A. | +27

CommentIn: Blood. 2023 May 11;141(19):2285-2286. - PMID 37166931

6

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice : Results From the US Lymphoma CAR T Consortium

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Wang, Y. | Jain, P. | Locke, F. | +26

7

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma

enthalten in: Haematologica | 2023

von Zurko, J. | Ramdial, J. | Shadman, M. | +39

8

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

enthalten in: Journal of hematology & oncology | 2022

von Shah, B. | Ghobadi, A. | Oluwole, O. | +27

9

Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma : Results from the US Lymphoma CAR-T Consortium

enthalten in: Clinical lymphoma, myeloma & leukemia | 2022

von Jacobs, M. | Jain, M. | Gao, F. | +23

10

Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas

enthalten in: Transplantation and cellular therapy | 2022

von Riedell, P. | Hwang, W. | Nastoupil, L. | +15

CommentIn: Transplant Cell Ther. 2022 Oct;28(10):621-622. - PMID 36202524